Significant movements have occurred recently around
Edwards Lifesciences Corporation (EW). Many institutional investors are taking positions in Edwards Lifesciences, with acquisitions and sales of shares by Groupama Asset Management, AIA Group Ltd, Stance Capital LLC, and Norinchukin Bank. The
CFO and VP of Edwards Lifesciences have also made notable transactions. The corporation main focus is heart therapeutics and aims to reach two million underserved heart patients by 2030. Despite some volatility, the company's valuation remains attractive to investors, with analysts maintaining a
'Moderate Buy' consensus. The company has communicated an upgraded outlook for 2025-2026 and has strong revenue growth, highlighted in the last quarter reports. Correspondingly,
Edwards Lifesciences stock has gained momentum, increasing by 14% over the past year.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Sat, 21 Mar 2026 21:16:38 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -4
